Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Harvard Bioscience manufactures precision instruments and apparatus for life science research, serving academic institutions, pharmaceutical companies, and biotech firms globally. The company operates through two segments: Cell & Molecular Technologies (microfluidics, cell culture systems) and Physiology & Behavior (surgical instruments, data acquisition systems for preclinical research). Currently experiencing significant operational distress with negative cash flow, high leverage (3.04x D/E), and deteriorating margins amid 16% revenue contraction.
Generates revenue through direct sales of specialized research equipment to academic labs, pharmaceutical R&D departments, and contract research organizations. Business model relies on recurring consumables revenue (pipette tips, tubing, sensors) and service contracts that provide 60-70% gross margins versus 50-55% on capital equipment. Pricing power derives from switching costs once labs integrate equipment into protocols and regulatory submissions. However, current 58.2% gross margin with negative operating margin (-6.6%) indicates severe SG&A burden and underutilization of manufacturing capacity.
NIH and European research funding levels - drives academic lab capital equipment budgets (40-45% of end market)
Pharmaceutical R&D spending trends - particularly preclinical research activity and drug development pipelines
Order flow from top 20 customers (typically concentrated with large pharma and CROs representing 30-40% of revenue)
Gross margin trajectory - ability to maintain 58%+ margins while absorbing fixed manufacturing costs
Liquidity events - covenant compliance, refinancing needs given 3.04x debt/equity and negative cash flow
Shift toward outsourced research models (CROs) and shared core facilities reducing individual lab equipment purchases - structural headwind to capital equipment sales
Technology disruption from organ-on-chip platforms and computational biology reducing demand for traditional animal research instrumentation
Consolidation among life science tool suppliers (Thermo Fisher, Danaher acquisitions) creating scale disadvantages for sub-$100M revenue players
Regulatory changes restricting animal research (EU Directive 2010/63/EU implementation) reducing addressable market for physiology segment
Competition from well-capitalized peers (Thermo Fisher, Danaher/Pall, Sartorius) with broader product portfolios and ability to bundle equipment sales
Pricing pressure from Chinese manufacturers (Longer Precision Pump, RWD Life Science) offering 40-50% lower prices on commodity products like syringe pumps
Customer bargaining power increasing as labs consolidate purchasing through group procurement organizations
Liquidity crisis risk - 0.81x current ratio with negative operating cash flow suggests potential working capital shortfall within 12 months without refinancing
Debt covenant breach risk - 3.04x debt/equity with negative EBITDA likely violates or approaches leverage covenant thresholds
Going concern risk - combination of negative margins (-13.2% net), cash burn, and high leverage creates existential threat without operational turnaround or capital injection
Asset impairment risk - goodwill and intangible assets likely material given acquisition history; revenue decline may trigger impairment charges
moderate-to-high - Revenue highly correlated with discretionary research spending by academic institutions and corporate R&D budgets. Economic downturns trigger lab budget cuts, delayed capital equipment purchases, and reduced NIH appropriations. However, pharmaceutical industry R&D spending (50% of market) demonstrates relative stability during recessions as drug development timelines extend 10-15 years. Current 16% revenue decline likely reflects combination of post-COVID normalization in life science spending and tighter biotech funding environment.
High sensitivity through multiple channels: (1) 3.04x debt/equity ratio means rising rates directly increase interest expense on floating-rate debt, (2) biotech customer funding constrained as venture capital and IPO markets contract with higher rates, reducing equipment orders, (3) valuation multiple compression as discount rates rise - currently trading at 0.3x P/S reflects distressed valuation. Federal funds rate increases from 2022-2023 likely contributed to biotech funding drought impacting order flow.
Significant exposure - Company's own credit profile deteriorating with negative EBITDA (EV/EBITDA of -1.4x) and 0.81x current ratio suggesting potential covenant pressure. Customer credit risk elevated as early-stage biotech customers face funding challenges. Vendor financing or extended payment terms may be strained. Refinancing risk material if credit spreads widen further given already stressed balance sheet.
Special situations / distressed value investors given 0.3x P/S valuation and turnaround potential if operations stabilize. Not suitable for growth investors (negative revenue growth) or income investors (no dividend, negative FCF). High-risk/high-reward profile attracts event-driven funds betting on restructuring, asset sales, or acquisition. Retail investors largely absent given micro-cap size and operational distress.
high - Micro-cap with limited liquidity, operational distress, and binary outcomes (successful turnaround vs bankruptcy/restructuring) create elevated volatility. 32.8% decline over 12 months with 27.4% drop in recent 3 months demonstrates downside volatility. Estimated beta above 1.5x given small-cap healthcare exposure and company-specific execution risk.